Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Increasing Costs In Cancer Care Are A Growing Factor In Decision-Making For Patients, Physicians, Society
When a cancer patient and his or her doctor discuss the value of a treatment option, the conversation usually centers on a consideration of the treatment"s medical benefits versus its possible side effects for the patient. Increasingly, however, as the already high costs of cancer care continue to rise, a full view of the patient"s welfare must also take into account the economic impact of the treatment on the patient and his or her family.
generic viagra online
Lost Molecule Is Lethal For Liver Cancer Cells In Mice
Scientists at Johns Hopkins have discovered a potential strategy for cancer therapy by focusing on what"s missing in tumors.
News of the day
For People With Overactive Bladders Botox Injections Can Significantly Improve Quality Of Life
Botox is well known for its cosmetic uses, but researchers have now found that it can also significantly improve people"s quality of life if they suffer from another problem that increases with age, an overactive bladder (OAB).
Health Insurance

Phase II Study Of Sunitinib In Men With Advanced Prostate Cancer

UroToday.com - In the Annals of Oncology, Dr. Dror Michaelson and associates reported Phase II data on the efficacy and safety of the tyrosine kinase inhibitor sunitinib in patients with castration-resistant prostate cancer (CRPC). Sunitinib inhibits vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), both elevated in prostate cancer (CaP). Two groups of patients were studied; group A, which was chemotherapy naç¯ve and group B, which had failed docetaxel. The primary endpoint was PSA decline >50% from baseline. Secondary endpoints included objective response rate, safety, tolerability and serum biomarkers. Treatment was in 6-week cycles, consisting of 50mg daily for 4 weeks followed by 2 weeks off. Concurrent treatment with bisphosphonates was permitted. Seventeen men in each group had data available for analysis. Only one patient in group A, and one patient in group B demonstrated a >50% PSA decline. Fourteen of 34 men had some PSA decline and 8 men (34%) had a >30% PSA decline. At 12-week analysis it was noted that radiographic improvements were present in some patients who nevertheless had increasing PSA levels. Based upon not having 2 or more PSA response criteria met, the study enrollment was not continued. Adverse events were primarily grade 1 or 2 and included nausea, fatigue, anorexia, taste disturbance, vomiting, diarrhea and skin rash. Regarding biomarkers, sVEGFR2, PDGFaa, and leptin all decreased but did not correlate with PSA. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR Ann Oncol. 2009 May;20(5):913-20. doi:10.1093/annonc/mdp111 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009